A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors

被引：0
|
作者：
Hope E. Uronis
Jingquan Jia
Johanna C. Bendell
Leigh Howard
Neal A. Ready
Paula H. Lee
Mark D. Starr
Andrew Dellinger
Herbert Pang
Andrew B. Nixon
Herbert I. Hurwitz
机构：
[1] Duke University Medical Center,Duke Cancer Institute
[2] Sarah Cannon Research Institute,Department of Biostatistics and Bioinformatics
[3] Duke University Medical Center,Brody School of Medicine
[4] East Carolina University,Department of Mathematics and Statistics
[5] Elon University,School of Public Health
[6] Li Ka Shing Faculty of Medicine,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2015年 / 75卷
关键词：
Intetumumab; Bevacizumab; Angiogenesis; Phase I;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：343 / 352
页数：9
相关论文
共 50 条
  • [31] Phase I study of oral S-1 in combination with oxaliplatin (oxali) and bevacizumab (bev) in patients with advanced solid tumors
    Zhang, J.
    Chung, K.
    Zergebel, C.
    Urrea, P.
    Quinones, M.
    Saltz, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [32] A phase I study of ombrabulin (O) combined with bevacizumab (B) in patients with advanced solid tumors
    Ong, Michael
    Del Conte, Gianluca
    Bahleda, Rastislav
    Mateo, Joaquin
    Damian, Silvia
    Perotti, Antonella
    Lassau, Nathalie
    Farace, Franoise
    Lovosgaldeano, Jimena
    Tunariu, Nina
    Hospitel, Marie
    Mariani, Paola
    Cohen, Patrick
    Capri, Giuseppe
    Soria, Jean-Charles
    Gianni, Luca
    Molife, L. Rhoda
    Sessa, Cristiana
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] Phase I study of ispinesib in combination with carboplatin in patients with advanced solid tumors.
    Jones, S. F.
    Plummer, E. R.
    Burris, H. A.
    Razak, A. R.
    Meluch, A. A.
    Bowen, C. J.
    Williams, D. H.
    Hodge, J. P.
    Dar, M. M.
    Calvert, A. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 85S - 85S
  • [34] Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study
    Munster, Pamela
    Iannotti, Nicholas
    Cho, Daniel C.
    Kirkwood, John M.
    Villaruz, Liza C.
    Gibney, Geoffrey T.
    Hodi, F. Stephen
    Mettu, Niharika B.
    Jones, Mark
    Bowman, Jill
    Smith, Michael
    Lakshminarayanan, Mani
    O'Day, Steven
    CANCER RESEARCH COMMUNICATIONS, 2023, 3 (12): : 2572 - 2584
  • [35] Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumors.
    Hollebecque, Antoine
    Bahleda, Rastislav
    Thery, Jean Christophe
    Faivre, Laura
    Le Deley, Marie-Cecile
    Paci, Angelo
    Varga, Andrea
    Gazzah, Anas
    Massard, Christophe
    Poinsignon, Vianney
    Malekzadeh, Katty
    Ribrag, Vincent
    Angevin, Eric
    Postel-Vinay, Sophie
    Gomez-Roca, Carlos Alberto
    Gharib, Myriam
    Dufour, Fabienne
    Soria, Jean-Charles
    Spano, Jean-Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [36] Phase I Study of Pazopanib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumors
    Tan, Antoinette R.
    Dowlati, Afshin
    Jones, Suzanne F.
    Infante, Jeffrey R.
    Nishioka, Jennifer
    Fang, Lei
    Hodge, Jeffrey P.
    Gainer, Shelby D.
    Arumugham, Thangam
    Suttle, A. Benjamin
    Dar, Mohammed M.
    Lager, Joanne J.
    Burris, Howard A., III
    ONCOLOGIST, 2010, 15 (12): : 1253 - 1261
  • [37] Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors
    Rangwala, Fatima
    Bendell, Johanna C.
    Kozloff, Mark F.
    Arrowood, Christy C.
    Dellinger, Andrew
    Meadows, Jennifer
    Tourt-Uhlig, Sandra
    Murphy, Jennifer
    Meadows, Kellen L.
    Starr, Aijing
    Broderick, Samuel
    Brady, John C.
    Cushman, Stephanie M.
    Morse, Michael A.
    Uronis, Hope E.
    Hsu, S. David
    Zafar, S. Yousuf
    Wallace, James
    Starodub, Alexander N.
    Strickler, John H.
    Pang, Herbert
    Nixon, Andrew B.
    Hurwitz, Herbert I.
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (04) : 700 - 709
  • [38] Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors
    Fatima Rangwala
    Johanna C. Bendell
    Mark F. Kozloff
    Christy C. Arrowood
    Andrew Dellinger
    Jennifer Meadows
    Sandra Tourt-Uhlig
    Jennifer Murphy
    Kellen L. Meadows
    Aijing Starr
    Samuel Broderick
    John C. Brady
    Stephanie M. Cushman
    Michael A. Morse
    Hope E. Uronis
    S. David Hsu
    S. Yousuf Zafar
    James Wallace
    Alexander N. Starodub
    John H. Strickler
    Herbert Pang
    Andrew B. Nixon
    Herbert I. Hurwitz
    Investigational New Drugs, 2014, 32 : 700 - 709
  • [39] Phase I dose-escalation study of plitidepsin in combination with bevacizumab in patients with refractory solid tumors
    Aspeslagh, Sandrine
    Awada, Ahmad
    Matos-Pita, Arturo S.
    Aftimos, Philippe
    Bahleda, Ratislav
    Varga, Andrea
    Soria, Jean-Charles
    ANTI-CANCER DRUGS, 2016, 27 (10) : 1021 - 1027
  • [40] Sunitinib and bevacizumab in advanced solid tumors: A phase I trial
    Cooney, M. M.
    Garcia, J. A.
    Elson, P.
    Mekhail, T.
    Dreicer, R.
    Nock, C. J.
    Bokar, J. A.
    Tyler, A.
    Beatty, K.
    Bukowski, R. M.
    Rini, B. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345